Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant atezolizumab plus dual HER2 blockade and epirubicin for HER2-positive early breast cancer
2019-002364-27Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Pathologic complete response (pCR) rate. Started Nov 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002364-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002364-27.